Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

VERNALIS PLC (VER)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/15 05:35:15 pm
8.75 GBp   -1.74%
12/15 VERNALIS : enters into research collaboration with Daiichi Sankyo
12/14 VERNALIS : AGM Statement
12/14 VERNALIS PLC : AGM Statement
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
12/11/2017 12/12/2017 12/13/2017 12/14/2017 12/15/2017 Date
11.75(c) 12(c) 12.5(c) 8.905(c) 8.75(c) Last
154 133 36 245 292 895 4 685 045 1 011 308 Volume
-4.08% +2.13% +4.17% -28.76% -1.74% Change
More quotes
Financials ( GBP)
Sales 2018 15,5 M
EBIT 2018 -34,4 M
Net income 2018 -35,1 M
Finance 2018 13,7 M
Yield 2018 -
Sales 2019 25,7 M
EBIT 2019 -30,8 M
Net income 2019 -31,8 M
Debt 2019 5,54 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 2,09x
EV / Sales2019 2,01x
Capitalization 46,1 M
More Financials
Company
Vernalis Plc is a commercial stage pharmaceutical company.Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of the antibiotic and amoxicillin; and frovatriptan, used for the acute treatment of migraine.Vernalis also develops and... 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
12/15 VERNALIS : enters into research collaboration with Daiichi Sankyo
12/14 VERNALIS : AGM Statement
12/14 VERNALIS PLC : AGM Statement
12/13 VERNALIS : enters into research collaboration with Daiichi Sankyo
12/13 VERNALIS : + Daiichi Sankyo Enter Collaboration
12/06 VERNALIS : and Servier Achieve Research Milestone in Third Oncology Collaboratio..
12/06 VERNALIS : and Servier Achieve Research Milestone
09/12 VERNALIS : Results Announcement for the year ended 30 June 2017
09/12 VERNALIS PLC : Results Announcement for the year ended 30 June 2017
09/07VERNALIS PLC : annual earnings release
More news
Sector news : Biotechnology & Medical Research - NEC
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15DJALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
12/13 France's Sanofi pins hopes on new drugs after setbacks
12/12 Sanofi investors hungry for drug progress and deal news
12/09 Tax-loss selling to pressure 2017's losers in December
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/12 Vernalis reports FY results
08/11 SNIPPET ROUNDUP : A Small Success For Galapagos And A Big One For Karius
04/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 23, 2017
04/21 FDA rejects Vernalis' marketing application cough/cold med CCP-07
02/21 Vernalis reports 1H results
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 0,43  GBP
Spread / Average Target 390%
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Sandford Sommer President & Chief Operating Officer
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Mike Wood Research Director
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-73.81%61
CELLTRION, INC.--.--%23 756
IQVIA HOLDINGS INC34.41%21 227
INCYTE CORPORATION-2.16%20 346
LONZA GROUP62.09%19 523
ALNYLAM PHARMACEUTICALS, INC.233.49%12 349